Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AXNX vs ABT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABT Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

ABT Overall Winner 6-Pillar Tally: AXNX 0 – 6 ABT Matrix Metrics: AXNX 2 – 8 ABT

As of Nov 20, 2026, Abbott Laboratories (ABT) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas ABT carries 42.6/100 (HOLD) at $103.00 (17.4x Forward P/E, 15.7% operating margin).

  • Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. ABT 42.6/100 HOLD), ABT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (15.7% vs. N/A operating margin) and revenue trajectory (+14.5% vs. N/A YoY).
  • Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ABT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXNX vs ABT
AXNX US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
52.1 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ABT NYSE Head-to-Head Winner
Abbott Laboratories
Pharmaceutical Preparations
$103.00
-0.84% 1D
Market Cap $179.9B
TTM Revenue $48.2B
Forward P/E 17.4x
Beta / 30D Vol 0.04β · 32% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.2%) with fading momentum, RSI 42
RSI-14: 41.8 · SMA20: $107.48 · SMA50: $103.89

6-Pillar Scorecard Institutional Category Breakdown (AXNX 0 – 6 ABT)

Columns: Metric · AXNX · ABT
1. Valuation Multiples ABT
Forward P/E N/M 17.4x
Trailing P/E N/M 38.8x
PEG Ratio N/M 1.50x
EV / Revenue N/M 4.3x
2. Growth & Scale ABT
Revenue Growth (YoY) N/A +14.5%
Earnings Growth (YoY) N/A -43.6%
TTM Revenue (USD) N/A $48.2B
Market Cap N/A $179.9B
3. Profitability & Quality ABT
Gross Margin N/A 57.2%
Operating Margin N/A 15.7%
Net Profit Margin N/A 9.8%
Return on Equity (ROE) N/A 9.1%
4. Balance Sheet & Cash Flow ABT
Cash Generation (TTM) N/A $11.5B EBITDA
Cash Flow Margin N/A 23.8% EBITDA Mgn
Net Cash / Leverage N/A ROE $27.1B Net Debt (0.61x D/E)
Dividend Yield None (0.00%) 2.41%
5. Options & Positioning ABT
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 112.5% (11th %ile)
Put/Call OI Skew N/A 0.39x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat ABT
OpEx & R&D Intensity N/A 41.5% of Rev ($20.0B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXNX (2) vs ABT (8)
Institutional Metric AXNX ABT Criterion Row Edge
Market Capitalization
Scale
N/A $179.9B Larger Scale ABT
Trailing P/E Ratio
Valuation
N/M 38.8x Lower Multiple ABT
Forward P/E Ratio
Valuation
N/M 17.4x Lower Multiple ABT
Revenue Growth (YoY)
Growth
N/A +14.5% Higher Growth ABT
Operating Margin (TTM)
Profitability
N/A 15.7% Higher Margin ABT
Net Profit Margin
Profitability
N/A 9.8% Higher Margin ABT
Return on Equity (ROE)
Capital Efficiency
N/A 9.1% Higher ROE ABT
52-Week Range Position
Momentum
50% ($0–$1) 42% ($82–$131) Stronger Trend AXNX
Beta / 30D Volatility
Risk Regime
N/A 0.04β · 32% Vol Lower Realized Risk ABT
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite AXNX
Trailing 12M Revenue (USD)
Operating Scale
N/A $48.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 57.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.50x PEG · 4.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $11.5B EBITDA ($27.1B Net Debt (0.61x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABT +27.02 pp
AXNX: -26.54% · ABT: +0.48%
3M Horizon AXNX +16.54 pp
AXNX: +16.92% · ABT: +0.38%
6M Horizon AXNX +16.54 pp
AXNX: +16.92% · ABT: +0.38%
1Y Horizon AXNX +16.54 pp
AXNX: +16.92% · ABT: +0.38%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs ABT. Trailing 12-month operating profitability (AXNX N/A vs ABT 15.7%) and valuation multiples (AXNX N/M vs ABT 17.4x Forward P/E) are benchmarked directly in Pillar 4 below.

AXNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48.2B
Gross Margin57.2%
Op. Margin15.7%
ROE / Fwd P/E9.1% · 17.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AXNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABT CONSOLIDATION
64d in phase · OBV DISTRIBUTION
Current IV 112.5%
IV Percentile 11th %ile
Put/Call OI Skew 0.39x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $107.45 · IV 27.2%

ABT Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($10,745)

Compare $10,745 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 27.2% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 4 $108 / $111 Bull Call Spread

Buy 1x $108C · Sell 1x $111C · 17d

Net Entry $55 Debit
T+5d @ +5% Move +$103 (+186%)
Max Risk / Buffer $55 Capped
5d Edge & Liquidity 2.0x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $100 / $95 Bull Put Spread

Sell 1x $100P · Buy 1x $95P · 31d

Net Entry $56 Credit
Max Credit / Yield +$56 (+12.6% RoM)
Max Risk / Buffer -7.5% Cushion ($444 Mgn)
5d Edge & Liquidity 83% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXNX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $179.9B market capitalization and 15.7% operating margin.
OpEx & R&D Reinvestment 41.5% of Rev ($20.0B)
90D Engineering Disclosures 0 Published

Investor FAQ AXNX vs ABT Key Questions & Quantitative Answers

As of Nov 20, 2026, Abbott Laboratories (ABT) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas ABT carries 42.6/100 (HOLD) at $103.00 (17.4x Forward P/E, 15.7% operating margin). Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. ABT 42.6/100 HOLD), ABT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (15.7% vs. N/A operating margin) and revenue trajectory (+14.5% vs. N/A YoY). Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ABT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABT leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABT at +14.5% YoY revenue growth and -43.6% YoY earnings growth on $48.2B TTM revenue (57.2% gross margin, 15.7% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $48.2B for ABT. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus 41.5% of Rev ($20.0B) (0 disclosures) for ABT.

ABT screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABT trades at 17.4x Forward P/E, 38.8x Trailing P/E, 1.50x PEG, and 4.3x EV/Revenue (23.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus ABT (9.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, ABT carries 112.5% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.39x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.04β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.